Targeted cancer therapy

By C. Sawyers. Nature, 2004

1,078 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/e2ef1d2046da7cd040099e7675c8a954853ea54a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

In Molecular Biology

In Oncology

Citations in the corpus

Mechanisms and insights into drug resistance in cancer (2013, neutral): “…including 5-fluorouracil and cytarabine (Raderer and Scheithauer, 1995; Guilhot et al., 1997; Druker et al., 2001; Kreitman et al., 2001; Tallman et al., 2002; Goldman and Melo, 2003; O’Brien et al., 2003; Sawyers, 2004; Kreitman, 2006; Ferrantini et al., 2007; Chin and Gray, 2008; Sellers, 2011).”
Role of Tyrosine Kinase Inhibitors in Cancer Therapy (2005, methodology): “This approach differs from the more empirical approach used in conventional cytotoxic chemotherapy, which has remained the mainstay of anticancer drug use over the past several decades (Sawyers, 2004).”
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers (2006, background): “cessful treatments to inhibit specific protein kinase such as imatinib for the BCR–ABL translocation or c-KIT mutation and trastuzumab for HER2 amplification have encouraged the concept of targeted therapy for human cancers.(2,3) The discovery that mutations of the tyrosine kinase (TK) domain of epi”
Characterizing the cancer genome in lung adenocarcinoma (2007, methodology): “Significant broad regions of amplification and deletion were identified by applying GISTIC with the default thresholds of 2.14/1.87 (log2 ratio of ±0.1).”
Guidelines for the welfare and use of animals in cancer research (2010, background): “In recent years the identification of the genes and pathways that give rise to cancer dependencies and vulnerabilities has taken us further towards the development of individualised, molecularly targeted therapies (Sawyers, 2004; Collins and Workman, 2006; Workman and de Bono, 2008).”
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics (2022, background): “Some of the promising inhibitor therapies which have been used to treat solid cancers are polyadenosine diphosphate-ribose polymerase inhibitors, angiogenesis inhibitors, histone deacetylase (HDAC) inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, poly (adenosine di-phosphate-ribose) po”
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (2005, background): “Although imatinib inhibits different kinases in various diseases (BCR-ABL in CML, KIT or PDGFR-alpha in gastrointestinal stromal tumors [GISTs], and PDGFR-alpha in hypereosinophilic syndrome [HES]) (reviewed in [14]), some tumors that become refractory to treatment with imatinib appear to have analo”
A Correction to the Review Titled "Rules for Modeling Signal-Transduction Systems" by W. S. Hlavacek et al. (2006, background): “Many diseases are caused by molecular changes that affect signal-transduction systems, and some of these diseases, such as chronic myelogenous leukemia, can now be treated by drugs that target signaling proteins, such as kinases ( 1 ).”
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity (2008, background): “The therapeutic approach of targeting oncogenic kinase activity has proved very valuable in oncology (5, 6).”
Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (2012, methodology): “The past decade has seen the advent of molecularly targeted agents capable of inhibiting specific pathways that are required for survival, proliferation, and metastasis of diseased cells (4, 5).”